Navigation Links
Dendreon Announces Election of Dr. David C. Stump to Board of Directors
Date:6/2/2010

SEATTLE, June 2 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that David C. Stump, M.D., has been elected to the Company's Board of Directors.  Dr. Stump is currently executive vice president of research and development for Human Genome Sciences, Inc. (Nasdaq: HGSI), where he has been a member of its management committee since 1999.

"We welcome Dave to Dendreon's Board of Directors.  With more than 20 years of experience in global drug development and clinical research, Dave is an ideal addition to our board, particularly as Dendreon initiates its ex-U.S. strategy and expands its clinical development program to develop new and innovative treatment options for cancer patients," said Richard B. Brewer, chairman of the Dendreon Board of Directors.  

Prior to joining Human Genome Sciences, Inc., Dr. Stump held positions of increasing responsibility over a decade at Genentech, Inc., including vice president of clinical research.  He was named a Genentech Fellow in 1996 for leadership of its cardiovascular drug development activities.  In his later roles he was also responsible for pulmonary, oncology, and neuroendocrine clinical development programs.  He served as a member of the research review, clinical review, and product development committees which were responsible for oversight of all internal and external research and development opportunities.  Prior to Genentech, Dr. Stump served as associate professor of medicine and biochemistry at the University of Vermont.  Dr. Stump received his M.D. from Indiana University and his bachelor's degree from Earlham College.  He completed his residency and fellowship training in internal medicine, hematology, and oncology at the University of Iowa and is board certified in all three areas.  He is currently a member of the Board of Directors for Sunesis Pharmaceuticals, Inc. as well as of the Boards of Trustees for Adventist HealthCare, Inc. and for Earlham College.

About Dendreon

Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first active cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer. Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , February 27, 2017 ... Stock-Callers.com for evaluation today, and they are: Anthera Pharmaceuticals ... Biosciences of California Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals ... article on ETF Trends, market observers are growing more ... administration could enact reforms to free cash held overseas ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... Rob Lowe ... public television series. This series, called "Informed," focuses on issues that are important to ... on the climate change issue, which has been a hot topic around the world ...
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... Island, NY (PRWEB) , ... February 24, 2017 , ... ... rate. Founded in late 2014, FireflySci had the goal of bringing their powerful ... that goal continues to shape the path that FireflySci is going on as they ...
Breaking Biology Technology:
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
Breaking Biology News(10 mins):